14.1 Visit Scheduling and Logistics

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

14.1 Visit Scheduling and Logistics

Key Takeaways Explain This Topic AI

Protocol visit windows dictate the exact timeframes during which study visits must occur to ensure valid data collection.

Missing a visit window constitutes a protocol deviation and must be documented and reported appropriately.

Effective coordination with ancillary departments (pharmacy, imaging, lab) is required to prevent Investigational Product (IP) waste and logistical delays.

Patient retention is heavily dependent on flexible, patient-centric scheduling and proactive communication.

Unscheduled visits require rapid logistical response to capture critical safety data and ensure the Principal Investigator evaluates the participant.

Last updated: October 2026

Managing Protocol Visit Windows

Visit scheduling is a core operational activity for a Clinical Research Coordinator (CRC). A protocol dictates not only which procedures must occur but when they must occur. Most protocols provide a visit window , defined as a specific timeframe around a target date during which a study visit must be completed. This standardization ensures that efficacy and safety data are collected at consistent intervals across all participants globally.

Target Date Calculation

The baseline or Day 1 visit typically serves as the anchor point for all subsequent visits. When scheduling future visits, the CRC must calculate the target date based on this anchor. For example, if Day 1 is January 1, Day 28 is exactly 27 days later (January 28).

Strict vs. Soft Windows

Visit windows vary significantly depending on the phase and nature of the trial:

Trial Phase/Type Typical Window Reason for Window Size

Phase I (PK/PD) ± 5 to 15 minutes Early phase trials rely heavily on precise pharmacokinetic (PK) blood draws to determine the half-life and maximum concentration of the drug. Delaying a draw by even 10 minutes can invalidate the data.

Phase II/III (Efficacy) ± 3 to 7 days These larger trials evaluate long-term efficacy and safety. A buffer of a few days accommodates patient work schedules, holidays, and minor illnesses without compromising the statistical power of the endpoint.

Long-Term Follow-up ± 14 to 30 days For survival follow-ups occurring years after treatment, a wide window is acceptable as the endpoints (e.g., overall survival) are macroscopic.

Managing Out-of-Window Visits

A visit occurring outside the designated window is a protocol deviation . The CRC must document this deviation, note the reason, and often submit it to the Institutional Review Board (IRB) and the sponsor. It is critical to proactively schedule visits early in the window. By scheduling early, the CRC builds in buffer time. If a patient cancels their appointment due to a flat tire on Day 26 (for a Day 28 ± 3 days window), the CRC still has until Day 31 to reschedule them without triggering a deviation. If the CRC originally scheduled them on Day 31 and they cancel, a deviation is inevitable.